30-day average of 14 articles · scale −100 to +100
Across 14 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Boston Scientific news is Neutral (+1)
on a scale from −100 to +100.
That is up 9 points from the previous 30 days (-8).
💊 WATCHMAN FLX Pro trials show noninferiority with reduced bleeding risks.
📉 Global recalls for Neuromodulation discs and microcatheters create operational risks.
Slightly Bullish +15
Boston Scientific stock faces recall scrutiny across device lines
AI-generated analysis
Key insights
📉 Boston Scientific faces operational risks from multiple Class II recalls involving Neuromodulation therapy discs and Direxion Torqueable Microcatheters distributed globally.
⚠️ Quality control issues could lead to rework costs, regulatory scrutiny, and disruption in interventional and neuromodulation product lines.
🔍 Recalls add pressure to the WATCHMAN and electrophysiology franchises which are already facing volume trends challenges.
💊 Recent trial results for the WATCHMAN FLX Pro device demonstrated noninferiority with reduced bleeding risks compared to dual antiplatelet therapy.
📈 Analysts project US$23.0 billion revenue and US$4.0 billion earnings by 2029 based on a 2.9% annual growth rate.
🚀 Optimistic estimates suggest potential for US$24.4 billion revenue and US$4.4 billion earnings by 2029 if execution targets are met.
🤝 The company's future performance depends on offsetting weaker franchises with its cardiovascular and MedSurg portfolios.
💰 Strategic growth relies on successful restructuring savings and the integration of the planned Penumbra acquisition.
📈 Bullish signals
💊Recent clinical trial results for the WATCHMAN FLX Pro device showed noninferiority for aspirin alone or reduced-dose NOAC regimens versus dual antiplatelet therapy at six months.
💊The findings from the WATCHMAN FLX Pro trials indicate similar ischemic stroke rates and less bleeding, which could support the franchise if left atrial appendage closure volumes stabilize.
📉 Risk factors
📉Multiple Class II recalls reported in 2026 involving firmware problems in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters raise potential remediation costs.
🔍Quality control issues associated with recent recalls add operational risk to a portfolio already facing pressure in electrophysiology and WATCHMAN product lines.
Article
Boston Scientific faces renewed investor scrutiny following multiple voluntary Class II device recalls reported in 2026, specifically involving firmware issues in Neuromodulation therapy discs and manufacturing defects in Direxion Torqueable Microcatheters. These quality control incidents introduce operational risks regarding potential remediation costs, tighter regulatory oversight, and possible disruption to the company's interventional and neuromodulation product lines.
The analysis highlights that these recall risks compound existing pressures within the WATCHMAN and electrophysiology franchises. While Simply Wall St notes that recent trial results for the WATCHMAN FLX Pro device show promising noninferiority outcomes, the broader investment case remains contingent on the company's cardiovascular and MedSurg portfolios offsetting weaker performance in specific areas.
Analysts project Boston Scientific to generate US$23.0 billion in revenue and US$4.0 billion in earnings by 2029, with more optimistic estimates reaching US$24.4 billion in revenue and US$4.4 billion in earnings. These long-term forecasts depend heavily on successful product quality maintenance, supply reliability, and the integration of the planned Penumbra acquisition to sustain growth.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Institutional investors have made mixed moves regarding Boston Scientific Corporation (NYSE:BSX) in recent quarters. Bleakley Financial Group LLC significantly reduced its stake by 51.3% in the first quarter, selling over 45,000 shares. Conversely, several other funds increased their positions; Ieq Capital LLC raised holdings by 97.0%, Main Street Financial Solutions by 35.3%, and HUB Investment Partners by 56.2%. Insider activity remains positive, with directors Edward J. Ludwig and David C. Habiger purchasing shares in May, bringing total insider ownership to 0.34%.
Financially, Boston Scientific reported strong Q1 results on April 22nd, beating earnings estimates of $0.79 with actual EPS of $0.80 and revenue of $5.20 billion against a consensus of $5.19 billion. The company achieved an 11.6% year-over-year revenue increase, maintaining a net margin of 17.29% and a return on equity of 19.17%. Looking ahead, the company has provided Q2 2026 guidance for EPS between $0.820 and $0.840, with full-year FY 2026 guidance ranging from $3.340 to $3.410.
The company announced a new stock buyback plan authorized on May 18th, permitting the repurchase of up to $5.00 billion in outstanding shares, which represents approximately 6.4% of its total share count. Analyst sentiment is mixed but generally leans positive with a consensus target price of $79.92. While some firms like Barclays and Goldman Sachs maintain overweight ratings with targets near $89-$71, others including Wells Fargo lowered targets to $55, and Weiss Ratings issued a sell rating.
📉 Bleakley Financial cut stake by 51.3% to 43,694 shares.
📈 Ieq Capital increased position by 97.0% adding $13.275 million.
💰 Q1 revenue hit $5.20 billion, beating estimates by $11 million.
🚀 Revenue grew 11.6% year-over-year with 17.29% net margin.
🔄 New $5.00 billion stock buyback authorized for up to 6.4%.
📉 Bleakley Financial Group LLC cut its stake in Boston Scientific by 51.3% in Q1, reducing holdings from roughly 89,693 shares to 43,694 shares.
📈 Ieq Capital LLC significantly increased its position by 97.0% in Q2, acquiring an additional 60,860 shares valued at $13.275 million.
💰 Boston Scientific reported Q1 revenue of $5.20 billion, beating the consensus estimate of $5.19 billion by $11 million.
📊 The company posted earnings per share of $0.80, surpassing analyst expectations of $0.79 for the quarter.
🚀 Revenue grew 11.6% year-over-year, demonstrating continued top-line expansion in the medical device sector.
💵 The business maintained a healthy net margin of 17.29% and a return on equity of 19.17%.
🔄 Management authorized a new $5.00 billion stock buyback program, allowing repurchase of up to 6.4% of outstanding shares.
📅 Q2 2026 EPS guidance is set between $0.820 and $0.840, with full-year FY 2026 guidance at $3.340-$3.410.
👔 Insider buying activity was notable in May, with directors Ludwig and Habiger purchasing shares totaling over $328,000.
📉 Analyst sentiment is mixed; Wells Fargo lowered its target to $55 while Goldman Sachs maintains a $71 target.
⚖️ Weiss Ratings downgraded the stock to a 'sell' rating, contrasting with a majority of analysts who hold 'buy' ratings.
🏢 Institutional ownership stands at 89.07%, indicating strong interest from major investment firms.
Bullish Signals
Beat Q1 EPS estimates at $0.80 versus $0.79 consensus.
Revenue grew 11.6% YoY to $5.20 billion.
Secured new $5.00 billion stock buyback authorization.
Ieq Capital increased stake by 97.0% in Q2.
Insiders bought $554,012 worth of stock in May.
Maintains strong net margin of 17.29% and ROE of 19.17%.
Risk Factors
Wells Fargo cut target to $55 from $75 due to valuation.
Barclays lowered target to $89 from $96 despite overweight rating.
Weiss Ratings downgraded stock from hold to sell in early July.
Bullish Signals
Boston Scientific beat Q1 earnings estimates with $0.80 EPS versus the consensus of $0.79, signaling operational strength.
Revenue increased by 11.6% year-over-year to reach $5.20 billion, exceeding analyst expectations of $5.19 billion.
The company secured a new $5.00 billion stock buyback authorization, suggesting management confidence in share value.
Ieq Capital LLC aggressively increased its stake by 97.0% in Q2, adding over 60,000 shares to its portfolio.
Insider buying was robust in May, with directors purchasing $554,012 worth of stock over the last ninety days.
The company maintains a strong net margin of 17.29% and a return on equity of 19.17%.
Risk Factors
Wells Fargo & Company lowered its price target to $55.00 from $75.00, citing potential valuation concerns.
Barclays reduced its price target from $96.00 to $89.00 while maintaining an overweight rating.
Weiss Ratings downgraded the stock from a 'hold' to a 'sell' rating in early July.
Analyst consensus targets vary widely, with some firms like Piper Sandler at $65.00 and Goldman Sachs at $71.00.
Boston Scientific (BSX) faces near-term headwinds as sales of its WATCHMAN device have slowed, with management citing workflow challenges and potential impacts from clinical trial developments and reimbursement dynamics. Analysts at Needham and Evercore ISI recently lowered their price targets to $57 and $65, respectively, reflecting expectations for sequentially flat sales in the second and third quarters.
Despite these specific product challenges, major analysts maintain Buy and Outperform ratings on the stock, citing the company's diversified portfolio and strong position across multiple high-growth medical markets. The firm is viewed as a well-positioned industry leader capable of leveraging favorable long-term trends in healthcare and medical device demand to drive future growth.
The article concludes that while short-term price target reductions acknowledge current risks, the constructive long-term investment outlook remains supported by Boston Scientific's broad product strength and market leadership. However, the text includes promotional content suggesting alternative AI stocks may offer higher returns, which is disregarded as boilerplate marketing.
📉 Needham analyst Mike Matson lowered BSX price target to $57.
📉 Evercore ISI reduced BSX price target to $65 with Outperform rating.
⚠️ WATCHMAN device sales slowed due to workflow and reimbursement issues.
💡 Analysts favor Boston Scientific for diversified portfolio and long-term growth.
🏢 Founded in 1979, Boston Scientific markets minimally invasive devices globally.
📉 Needham analyst Mike Matson lowered the price target on Boston Scientific (BSX) to $57 from $77 while maintaining a Buy rating.
📉 Evercore ISI reduced its price target on BSX to $65 from $78 but reiterated an Outperform rating.
⚠️ Sales of the WATCHMAN device have slowed, with expectations for flat performance in Q2 and Q3 due to workflow issues and reimbursement dynamics.
🏥 Management attributes the WATCHMAN slowdown partly to workflow-related challenges affecting adoption rates.
💡 Analysts view Boston Scientific favorably due to its diversified portfolio strength and long-term growth opportunities in medical devices.
📈 The company is considered a well-positioned industry leader benefiting from favorable long-term healthcare demand trends.
🏢 Founded in 1979, Boston Scientific is headquartered in Marlborough, Massachusetts, and markets minimally invasive medical devices globally.
Equitable Trust Co. established a new position in Boston Scientific Corporation (BSX) during the first quarter by purchasing 12,912 shares valued at approximately $810,000. Several other institutional investors also increased their stakes, including Whipplewood Advisors LLC, which boosted its holdings by over 1,700%, and Resona Asset Management Co. Ltd., adding to a position worth nearly $29 million. Collectively, institutional investors own 89.07% of the company's outstanding stock.
Insider trading activity shows bullish sentiment as directors Edward J. Ludwig and Cheryl Pegus purchased shares totaling over $300,000 in late May. In the last three months, insiders have collectively bought 9,800 shares worth approximately $554,000, representing a 16.44% increase for Director Ludwig. Company insiders currently hold 0.34% of the total stock.
Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, an 11.6% year-over-year increase, and earnings per share of $0.80 that beat analyst estimates. The company has authorized a new $5.00 billion share repurchase program, signaling management's confidence in the stock's valuation and commitment to returning capital to shareholders.
DSM Capital Partners LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 11,846.4% in the first quarter, purchasing an additional 559,625 shares to hold a total of 564,349 shares valued at $35.4 million. Other institutional investors also adjusted their positions, with Ieq Capital LLC increasing its stake by 97.0% and Main Street Financial Solutions growing holdings by 35.3%. Corporate insiders, including directors Cheryl Pegus and David C. Habiger, collectively acquired 9,800 shares worth $554,012 in the last quarter, while institutional ownership remains high at 89.07%.
Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, beating analyst expectations of $5.19 billion and representing an 11.6% year-over-year increase. The company posted earnings per share (EPS) of $0.80, surpassing the consensus estimate of $0.79, alongside a return on equity of 19.17% and a net margin of 17.29%. Management has set guidance for Q2 2026 EPS between $0.820 and $0.840, and full-year 2026 EPS between $3.340 and $3.410.
In a move signaling confidence in its stock value, Boston Scientific's Board of Directors authorized a new share buyback plan on May 18th to repurchase up to $5.00 billion in shares, which could account for approximately 6.4% of the outstanding float. Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a price target of $81.32, though some firms like Citigroup and Canaccord Genuity recently lowered their price targets to $70.00 while maintaining buy ratings.
📈 DSM Capital Partners increased Boston Scientific holdings by 11,846.4% to $35.4 million.
📊 Q1 revenue hit $5.20 billion, beating estimates with an 11.6% year-over-year rise.
💰 EPS reached $0.80, surpassing the $0.79 consensus estimate by $0.01.
🔄 Board authorized a new $5.00 billion share repurchase program.
📉 Citigroup lowered price target to $70.00 while maintaining a 'buy' rating.
📈 DSM Capital Partners LLC increased its position in Boston Scientific by 11,846.4% in Q1, adding 559,625 shares to a total holding of 564,349 shares valued at $35.4 million.
📊 The company reported Q1 revenue of $5.20 billion, an 11.6% increase year-over-year, beating analyst estimates of $5.19 billion.
💰 Boston Scientific posted EPS of $0.80 for the quarter, exceeding the consensus estimate of $0.79 by $0.01.
🔄 The Board authorized a new share repurchase program allowing the company to buy back up to $5.00 billion in shares.
📉 Analyst Citigroup lowered its price target from $87.00 to $70.00 while maintaining a 'buy' rating on the stock.
👥 Corporate insiders acquired 9,800 shares worth $554,012 over the last quarter, with director David C. Habiger increasing his stake by 19.35%.
📅 The company set Q2 2026 EPS guidance between $0.820 and $0.840, and full-year 2026 EPS guidance between $3.340 and $3.410.
🏛️ Institutional investors own 89.07% of the company's outstanding shares, indicating strong institutional confidence.
Bullish Signals
DSM Capital increased position by 11,846.4%, adding over half a million shares.
Revenue beat expectations with $5.20 billion sales, up 11.6% year-over-year.
Earnings exceeded estimates at $0.80 EPS versus $0.79 consensus.
Management launched $5.00 billion buyback program for up to 6.4% of shares.
Insiders bought nearly $554,000 worth of stock last quarter.
Risk Factors
Analyst Citigroup cut price target from $87.00 to $70.00.
Wall Street Zen and Daiwa downgraded ratings to hold.
Bullish Signals
DSM Capital Partners LLC executed a massive position increase of 11,846.4%, adding over half a million shares to its portfolio.
The company beat quarterly revenue expectations with $5.20 billion in sales, up 11.6% from the prior year.
Boston Scientific exceeded earnings estimates with $0.80 EPS compared to the consensus of $0.79.
Management initiated a substantial $5.00 billion share buyback program, authorizing the repurchase of up to 6.4% of shares.
Corporate insiders collectively purchased nearly $554,000 worth of stock in the last quarter, signaling internal confidence.
Risk Factors
Analyst Citigroup reduced its price target from $87.00 to $70.00, reflecting a more conservative valuation outlook.
Wall Street Zen and Daiwa Securities Group downgraded their ratings from 'buy' or 'strong-buy' to 'hold', indicating some caution.
Elevation Point Wealth Partners LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 429.8% in the first quarter, adding 64,908 shares to reach a total holding of 80,011 shares valued at $5.02 million. Other institutional investors also adjusted positions, with FWL Investment Management LLC, Swiss RE Ltd., and Garton & Associates Financial Advisors LLC establishing new positions worth approximately $26,000 each in the second or fourth quarters.
Company insiders demonstrated bullish sentiment through recent purchases. Director Cheryl Pegus acquired 1,770 shares for roughly $100,000, while Director David C. Habiger bought 2,250 shares for about $126,000, increasing his personal stake by 19.35%. Collectively, insiders purchased 9,800 shares valued at over $554,000 in the last three months, though they still hold only 0.34% of the company's total stock.
Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, beating estimates by $10 million and growing 11.6% year-over-year. The company posted earnings per share (EPS) of $0.80 versus a consensus of $0.79, achieving a net margin of 17.29%. Management provided guidance for Q2 2026 EPS between $0.82 and $0.84, with full-year 2026 EPS expectations ranging from $3.34 to $3.41.
The company announced a new $5 billion stock repurchase program authorized by its board on May 18th, allowing the reacquisition of up to 6.4% of outstanding shares. Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Moderate Buy' and a target price of $83.36, despite recent downgrades from Wolfe Research and Wall Street Zen.
📈 Elevation Point Wealth raised stake 429.8% to $5.02 million holding.
💼 Insiders bought 9,800 shares worth $554,012 in last three months.
💰 Q1 revenue hit $5.20 billion, beating estimates by $10 million.
🚀 Management raised Q2 EPS guidance to $0.82-$0.84 range.
🔄 Board authorized new $5 billion share repurchase program.
📈 Elevation Point Wealth Partners LLC raised its stake by 429.8% in Q1, adding 64,908 shares to a total holding of 80,011 shares valued at $5.02 million.
🏦 Several other institutions including FWL Investment Management LLC and Swiss RE Ltd. established new positions worth approximately $26,000 each.
💼 Director Cheryl Pegus purchased 1,770 shares for $99,987.30, while Director David C. Habiger acquired 2,250 shares for $125,820 on May 20th.
📊 Insiders collectively bought 9,800 shares valued at $554,012 over the last three months, representing a net increase in their holdings.
💰 The company reported Q1 revenue of $5.20 billion, an 11.6% year-over-year increase that beat analyst estimates by $10 million.
📉 Earnings per share reached $0.80, surpassing the consensus estimate of $0.79 with a net margin of 17.29% and ROE of 19.17%.
🚀 Management raised Q2 2026 EPS guidance to a range of $0.82-$0.84 and set full-year 2026 EPS guidance between $3.34-$3.41.
🔄 The board authorized a new $5 billion share repurchase program, permitting the buyback of up to 6.4% of outstanding shares.
📉 Wolfe Research downgraded the stock from 'outperform' to 'peer perform', while Barclays lowered its price target from $96.00 to $89.00.
📈 Conversely, Needham & Company restated a 'buy' rating with a $77.00 target, and BTIG Research maintained a 'buy' with a $65.00 objective.
🎯 The consensus analyst rating is 'Moderate Buy' with an average price target of $83.36 based on MarketBeat data.
🏥 Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, urologic, pulmonary, and chronic pain conditions.
Bullish Signals
Insiders bought 9,800 shares worth over $554,000 recently.
Q1 revenue grew 11.6% to $5.20 billion.
EPS beat expectations at $0.80 versus $0.79 consensus.
Management raised full-year 2026 EPS guidance to $3.34-$3.41.
Board authorized a $5 billion stock repurchase program.
Risk Factors
Wolfe Research downgraded stock from outperform to peer perform.
Barclays cut price target from $96.00 to $89.00.
Wall Street Zen lowered rating from buy to hold.
Bullish Signals
Elevation Point Wealth Partners LLC significantly increased its position by 429.8% in Q1, adding 64,908 shares to a total holding of 80,011 shares valued at $5.02 million.
Company insiders purchased 9,800 shares worth over $554,000 in the last three months, signaling confidence in the stock's near-term prospects.
Q1 revenue of $5.20 billion exceeded analyst estimates by $10 million and grew 11.6% year-over-year, demonstrating strong top-line growth.
The company beat Q1 EPS expectations with a result of $0.80 versus the consensus of $0.79, indicating operational efficiency.
Management raised full-year 2026 EPS guidance to a range of $3.34-$3.41, suggesting confidence in future performance.
The board authorized a substantial $5 billion stock repurchase program, allowing the buyback of up to 6.4% of outstanding shares.
Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $83.36, reflecting overall market confidence.
Risk Factors
Wolfe Research downgraded the stock from 'outperform' to 'peer perform', indicating a reduction in growth expectations relative to peers.
Barclays decreased its price target from $96.00 to $89.00, suggesting a more conservative valuation outlook for the company.
Wall Street Zen lowered its rating from 'buy' to 'hold', reflecting mixed sentiment among some analysts regarding current valuations.
Boston Scientific (BSX) faces mixed market sentiment following an analyst downgrade driven by softer demand for its Watchman device and concerns over procedure bundling. The stock exhibits technical weakness near multi-year lows, with investors citing recent recalls and regional pacemaker issues as contributing factors to a cautious outlook despite the broader medtech sector showing tentative signs of recovery.
Despite the negative chatter, fundamental financial performance remains robust, with Q1 2026 revenues reaching $5.2 billion, representing an 11.58% year-over-year increase. Institutional investor activity is highly polarized in Q1 2026, with major firms like FMR LLC and Capital World Investors significantly reducing positions, while Wellington Management and Franklin Resources aggressively increased their holdings.
Insider trading data reveals a split narrative: CEO Michael Mahoney sold over $15 million in shares, whereas other executives and members of Congress have been net buyers. Wall Street consensus remains cautiously optimistic with multiple buy ratings from firms like BTIG and Needham, though recent price targets from analysts at Stifel and Jefferies hover around the low-to-mid $60s.
Analyst price targets for BSX currently range from $64 to $74, with a median target of $77.5 set over the last six months. The company continues to generate significant award payments related to its TheraspHERE Y-90 radiopharmaceuticals, highlighting ongoing revenue streams in specialized medical treatments.
📉 Negative sentiment follows Watchman demand drop and bundling pressures.
📊 Q1 2026 revenue surged 11.58% to $5.2 billion.
🏦 Institutional holdings split: FMR down 23.8%, Wellington up 94%.
💼 CEO sold $15M shares over six months.
📈 Wall Street maintains Buy ratings with median target of $77.5.
📉 Analyst sentiment turned negative after a price target cut linked to softer demand for the Watchman device and bundling pressures.
📊 Q1 2026 revenues surged 11.58% year-over-year to reach $5.2 billion, demonstrating strong underlying business growth.
🏦 Major institutional investors like FMR LLC reduced holdings by 23.8%, while Wellington Management increased positions by 94% in Q1 2026.
💼 CEO Michael Mahoney sold 160,901 shares worth approximately $15 million over the past six months.
📈 Multiple Wall Street firms including BTIG and Needham maintain 'Buy' ratings on the stock.
🎯 Recent analyst price targets range from $64 to $74, with a median target of $77.5.
⚠️ Market concerns persist regarding recent product recalls and regional pacemaker issues affecting the stock's technical chart.
💰 The company generated $23.7 million in award payments over the last year, primarily from TheraspHERE Y-90 products.
Bullish Signals
Q1 2026 revenue rose 11.58% to $5.2 billion.
Wellington Management added 9.1M shares (+94.0%).
Franklin Resources added 8.8M shares (+155.4%).
Two Sigma increased holdings by 6.9M shares (+280.8%).
BTIG, Needham, and Truist issued Buy ratings.
Congress members bought five shares of BSX stock.
Risk Factors
Analyst lowered targets due to softer Watchman device demand.
Stock trades near multi-year lows with put seller pressure.
Recent recalls and pacemaker issues fuel cautious market tone.
FMR LLC removed 23.1 million shares (-23.8%) in Q1 2026.
Capital World reduced position by 11.8 million shares (-43.6%).
CEO sold 160,901 shares for $15 million over six months.
Bullish Signals
Q1 2026 revenue increased by 11.58% to $5.2 billion compared to the prior year.
Wellington Management Group LLP added 9.1 million shares (+94.0%) to its portfolio in Q1 2026.
Franklin Resources Inc added 8.8 million shares (+155.4%) to its portfolio in Q1 2026.
Two Sigma Investments, LP increased holdings by 6.9 million shares (+280.8%) in Q1 2026.
Three major firms (BTIG, Needham, Truist Securities) issued 'Buy' ratings on the stock recently.
Members of Congress have made five purchases and zero sales of BSX stock in the past six months.
Risk Factors
An analyst lowered price targets citing softer demand for the Watchman device and bundling pressures.
The stock is trading near multi-year lows with ongoing pressure from put sellers.
Recent recalls and regional pacemaker issues are contributing to a cautious market tone.
FMR LLC removed 23.1 million shares (-23.8%) from its portfolio in Q1 2026.
Capital World Investors reduced their position by 11.8 million shares (-43.6%) in Q1 2026.
CEO Michael Mahoney sold 160,901 shares for an estimated $15 million over the last six months.
Cornerstone Wealth Group LLC significantly increased its stake in Boston Scientific Corporation (NYSE:BSX) by 1,323.9% in the first quarter, acquiring an additional 59,722 shares to hold a total of 64,233 shares valued at $3.82 million. Several other institutional investors also adjusted their positions, with Border to Coast Pensions Partnership adding a new stake worth approximately $24.34 million and Pictet Asset Management boosting its holdings by 19.1% to own over 5.12 million shares.
Analyst sentiment remains mixed regarding the medical device company's valuation. UBS Group lowered its price target from $120.00 to $105.00 while maintaining a 'buy' rating, and Leerink Partners reduced its target from $87.00 to $74.00. Conversely, Needham & Company reaffirmed a 'buy' rating with a $77.00 objective, and Oppenheimer set a target of $90.00. The consensus rating is currently a 'Moderate Buy' with an average price target of $83.36.
Financially, Boston Scientific reported strong performance in the last quarter, beating earnings estimates with $0.80 EPS on revenue of $5.20 billion, which represented an 11.6% year-over-year increase. The company has set guidance for Q2 2026 EPS between $0.82 and $0.84 and full-year 2026 EPS between $3.34 and $3.41. Additionally, the Board of Directors approved a new share buyback program authorizing the repurchase of up to $5.00 billion in shares.
Insider activity shows continued confidence from company leadership, with Director David C. Habiger purchasing 2,250 shares and Director Cheryl Pegus acquiring 1,770 shares on May 20th. Combined with the recent buyback authorization, these actions suggest management views the stock as undervalued despite the current trading price of $44.16 being below its 50-day and 200-day moving averages.
📈 Cornerstone Wealth increased stake by 1,323.9% to 64,233 shares.
💰 Border to Coast Pensions bought $24.34 million new stake.
📉 UBS lowered price target to $105 while keeping 'buy' rating.
💵 Q4 earnings beat estimates at $0.80 EPS on $5.20B revenue.
🚀 Board approved $5 billion share buyback program authorization.
📈 Cornerstone Wealth Group LLC increased its stake in Boston Scientific by 1,323.9% in Q1, adding 59,722 shares to a total holding of 64,233 shares.
💰 Border to Coast Pensions Partnership purchased a new stake worth approximately $24.34 million in the first quarter.
📉 UBS Group lowered its price target from $120.00 to $105.00 while maintaining a 'buy' rating on the stock.
📈 Needham & Company reaffirmed a 'buy' rating with a price objective of $77.00 for Boston Scientific shares.
💵 The company reported Q4 earnings of $0.80 EPS, beating analyst estimates of $0.79 on revenue of $5.20 billion.
📊 Revenue grew 11.6% year-over-year to $5.20 billion, exceeding the consensus estimate of $5.19 billion.
🚀 The Board of Directors approved a new share buyback program authorizing the repurchase of up to $5.00 billion in shares.
👔 Director David C. Habiger purchased 2,250 shares at an average price of $55.92, increasing his position by 19.35%.
📉 The stock currently trades at $44.16, which is below its 50-day moving average of $52.87 and 200-day moving average of $71.13.
🎯 Analyst consensus target price stands at $83.36 with a 'Moderate Buy' rating based on data from MarketBeat.com.
Bullish Signals
Cornerstone Wealth Group increased position by 1,323.9%.
Border to Coast Pensions added $24.34 million stake.
Pictet Asset Management boosted position by 19.1%.
Boston Scientific announced a definitive agreement to acquire medtech firm Penumbra in a deal valued at approximately $14.5 billion, marking the company's largest acquisition in two decades. The transaction is expected to be completed in 2026 and will significantly expand Boston Scientific's cardiovascular device portfolio with differentiated technologies for treating conditions including stroke, pulmonary embolism, heart attack, and aneurysms.
The deal values Penumbra at $374 per share, representing a premium of roughly 19.3% to its last closing price. Shareholders have the option to receive payment in cash or stock, with the transaction structured as approximately 73% cash and 27% stock. Upon completion, Penumbra's CEO Adam Elsesser will join Boston Scientific's board, integrating the California-headquartered firm into the Massachusetts-based company's operations.
Boston Scientific stated that adding Penumbra's products is expected to improve revenue and margins over time, capitalizing on rising demand driven by an aging population. The acquisition comes as the company recently raised its annual profit forecast due to strong heart device demand, positioning it for growth in a sector analysts expect to see a wave of mega-mergers in 2026.
Shares of Boston Scientific jumped over 13% to $354.70 in premarket trading following the announcement. This major deal follows a series of smaller acquisitions last year, including stakes in Nalu Medical and Bolt Medical, as the company continues to bolster its pain-management and cardiac pipelines through strategic M&A activity.
📈 Boston Scientific acquires Penumbra for $14.5 billion in largest 20-year deal.
💰 Deal values Penumbra at $374/share, a 19.3% premium to closing price.
🤝 Payment structure is roughly 73% cash and 27% stock for shareholders.
📅 Transaction expected to close in 2026 with CEO joining Boston Scientific board.
📈 Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion, its largest deal in two decades.
💰 The transaction values Penumbra at $374 per share, a 19.3% premium to the last closing price.
🤝 Payment structure consists of roughly 73% cash and 27% stock for Penumbra shareholders.
📅 The deal is expected to close in 2026 with CEO Adam Elsesser joining Boston Scientific's board.
❤️ Penumbra brings a comprehensive portfolio treating stroke, pulmonary embolism, heart attack, and aneurysms.
💵 Penumbra is projected to generate about $1.4 billion in sales for 2025.
📈 Boston Scientific recently raised its annual profit forecast due to strong demand for heart devices.
🚀 Shares of Boston Scientific surged over 13% to $354.70 in premarket trading on the news.
🔬 The acquisition aims to improve revenue and margins over time through product portfolio expansion.
🏭 This follows a trend of smaller deals last year including acquisitions of Nalu Medical and Bolt Medical.
Bullish Signals
Acquired Penumbra for $14.5 billion, largest deal in two decades.
Raised annual profit forecast due to robust heart device demand.
Shares jumped 13% to $354.70 in premarket trading.
Penumbra expected to contribute $1.4 billion in sales in 2025.
Deal expands capabilities in treating stroke and pulmonary embolism.
Bullish Signals
Boston Scientific announced a $14.5 billion acquisition of Penumbra, its largest deal in two decades, signaling strong strategic growth.
The company recently raised its annual profit forecast due to robust demand for its heart device portfolio.
Shares jumped over 13% to $354.70 in premarket trading, reflecting immediate market confidence in the deal.
Penumbra is expected to contribute approximately $1.4 billion in sales in 2025, adding significant revenue scale.
The acquisition expands Boston Scientific's capabilities in treating critical conditions like stroke and pulmonary embolism with differentiated devices.
Management explicitly stated the deal will help improve revenue and margins over time.
Boston Scientific's Watchman heart device revenue is expected to remain flat through Q3 2026 as physicians increasingly implant the device during combined cardiac procedures rather than as standalone treatments. This shift in clinical practice reduces standalone procedure volumes, altering the growth trajectory for this specific product line and requiring the company to adjust its strategic planning.
The news arrives amidst significant pressure on Boston Scientific's stock, which has declined 56.2% over the past year and is trading around $45.6. The flat revenue outlook for Watchman coincides with several brokers cutting price targets, reflecting investor concerns that advanced cardiac procedures may not sustain previous growth rates without interruption.
Analysts view this development as a key risk to Boston Scientific's ability to meet longer-term revenue targets, particularly given softer trends in electrophysiology. However, the company maintains a diversified portfolio including MedSurg and recent acquisitions like Axonics, which some analysts believe can provide support even as expectations for the Watchman line are reset.
Investors are advised to monitor whether combined procedures stabilize overall device utilization and how management balances capital allocation between buybacks, acquisitions, and balance sheet flexibility. The situation highlights a broader industry challenge where peers like Abbott and Medtronic also face pressure in medical devices.
📉 Revenue flat through Q3 2026 as standalone procedures decline.
📊 Stock down 56.2% year-over-year, trading near $45.60.
🏥 Physicians shifting to combined surgeries changes standard of care.
💼 Diversified portfolio may offset Watchman growth constraints.
📉 Watchman revenue is projected to be flat through Q3 2026 due to doctors combining the procedure with other heart surgeries instead of performing it standalone.
📊 The stock has fallen 56.2% over the last year and is down 21.1% in the past month, trading near $45.6.
⚠️ Brokers have cut price targets as analysts worry that reduced standalone volumes could weigh on confidence in hitting long-term revenue goals.
🏥 The shift reflects a change in standard of care where physicians are rethinking procedure planning for left atrial appendage closure.
💼 Boston Scientific maintains a diversified cardiovascular and MedSurg portfolio, including acquisitions like Axonics and Silk Road.
🔍 Investors need to track if combined procedures become a lasting standard that stabilizes overall device utilization despite lower standalone numbers.
📉 Peers such as Abbott and Medtronic are also facing pressure in the medical device sector, adding context to the broader industry environment.
💰 Management faces decisions on whether to continue large-scale buybacks and acquisitions or prioritize balance sheet flexibility during this reset.
🎯 The narrative suggests that while Watchman growth is constrained, other parts of the portfolio may still support above-market procedure growth.
Bullish Signals
Diversified portfolio supports business despite Watchman reset.
Sharp price decline creates room for sentiment improvement.
Risk Factors
Flat Watchman revenue expectations through Q3 2026 challenge growth assumptions.
Slower procedures and soft electrophysiology trends could suppress overall growth.
Repeated estimate cuts erode confidence in hitting long-term revenue targets.
Stock dropped 56.2% last year and 51.9% year-to-date.
Bullish Signals
Boston Scientific possesses a diversified cardiovascular and MedSurg portfolio that analysts view as supportive even as Watchman expectations are reset.
The sharp decline in the stock price over the past year may create scope for sentiment to improve if execution stabilizes and constructive analyst narratives gain traction.
Risk Factors
Flat revenue expectations for the Watchman product line through Q3 2026 directly challenge previous growth assumptions tied to procedure volume.
A prolonged slowdown in Watchman procedures coupled with softer electrophysiology trends could keep overall company growth below investor expectations.
Repeated estimate cuts across Watchman and electrophysiology sectors may erode confidence in Boston Scientific's ability to hit longer-term revenue targets.
The stock has underperformed significantly, dropping 56.2% over the last year and 51.9% year-to-date, indicating sustained market skepticism.
BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 45.1% during the first quarter, selling 58,923 shares to hold a remaining position of 71,593 shares valued at approximately $4.49 million. While this major institutional holder trimmed its exposure, other funds like FWL Investment Management and Swiss RE Ltd. established new positions worth roughly $26,000 each in the second and fourth quarters respectively. The stock remains heavily held by institutions at 89.07%, though insider ownership is low at 0.34%.
Analyst sentiment for Boston Scientific is mixed but generally positive, with an average rating of 'Moderate Buy' and a consensus price target of $85.08. Recent reports include Citigroup lowering its target to $70.00 while maintaining a 'buy' rating, UBS Group cutting its target from $120.00 to $105.00 with a 'buy' rating, and Piper Sandler setting a $65.00 target with an 'overweight' rating. Conversely, Wall Street Zen downgraded the stock to a 'hold', reflecting varied perspectives on the company's valuation and future prospects.
Financially, Boston Scientific reported strong Q1 2026 results with revenue of $5.20 billion, beating estimates by $10 million, and earnings per share of $0.80 versus a consensus of $0.79. The company grew revenue by 11.6% year-over-year and maintains healthy financial ratios including a debt-to-equity ratio of 0.42 and a P/E ratio of 18.53. Management has set Q2 2026 EPS guidance between $0.820 and $0.840, with full-year 2026 expectations ranging from $3.340 to $3.410.
The company announced a new share repurchase program authorized on May 18th, allowing it to buy back up to $5.00 billion in shares, representing roughly 6.4% of its outstanding stock. This initiative signals management's confidence in the share price and commitment to returning capital to shareholders. Trading recently opened at $44.30, well below its 200-day moving average of $72.44 but above its 52-week low of $44.05, suggesting potential volatility as the stock navigates analyst target adjustments.
📉 BI Asset Management sold 58,923 shares, retaining a $4.49 million position.
📈 Colonial Trust Co SC increased stake by 502.2% to own 277 shares.
💰 Director Edward J. Ludwig bought 3,580 shares at $56.68.
📊 Q1 revenue hit $5.20 billion, beating estimates of $5.19 billion.
💹 EPS reached $0.80, surpassing the $0.79 consensus estimate.
📉 BI Asset Management reduced its BSX holdings by 45.1% in Q1, selling 58,923 shares while retaining a $4.49 million position.
📈 Other funds including Colonial Trust Co SC increased their stakes significantly, with Colonial growing its position by 502.2% to own 277 shares.
💰 Insider Director Edward J. Ludwig purchased 3,580 shares at $56.68, increasing his personal holding by 16.44%.
📊 Q1 2026 revenue reached $5.20 billion, an 11.6% increase year-over-year, beating analyst estimates of $5.19 billion.
💹 Earnings per share for the quarter were $0.80, surpassing the consensus estimate of $0.79 by $0.01.
🎯 Analyst consensus price target is set at $85.08 with an average rating of 'Moderate Buy' across major Wall Street firms.
🔄 Citigroup lowered its price target to $70.00 while maintaining a 'buy' rating, indicating a more conservative valuation view.
💸 The board approved a new $5.00 billion share repurchase program authorized on May 18th to buy back up to 6.4% of shares.
📉 Stock price opened at $44.30, trading significantly below the 200-day simple moving average of $72.44.
🏥 Boston Scientific focuses on less-invasive medical procedures for cardiovascular, digestive, and urologic conditions.
Bullish Signals
Beat Q1 EPS estimates at $0.80 vs $0.79 consensus.
Colonial Trust Co SC holdings increased over 500%.
Insiders bought $328,734.40 in shares recently.
Low debt-to-equity ratio of 0.42 and current ratio of 1.90.
Risk Factors
Wall Street Zen downgraded stock from buy to hold.
Citigroup and UBS lowered price targets suggesting downside risk.
Price at $44.30 is below 200-day moving average of $72.44.
Bullish Signals
The company beat Q1 earnings estimates with EPS of $0.80 versus the consensus of $0.79, demonstrating operational strength.
Revenue grew by 11.6% year-over-year to $5.20 billion, indicating robust demand for its medical device portfolio.
Management has authorized a substantial $5.00 billion share repurchase program, signaling confidence in the stock's undervaluation.
Major institutions like Colonial Trust Co SC increased their positions significantly, with Colonial growing holdings by over 500%.
Insiders have been active buyers, with Directors Ludwig and Habiger purchasing shares totaling $328,734.40 in recent transactions.
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.42 and a healthy current ratio of 1.90.
Risk Factors
Wall Street Zen downgraded the stock from 'buy' to 'hold', reflecting concerns that may not be fully priced in by other analysts.
Several major banks including Citigroup and UBS Group lowered their price targets, suggesting potential downside risk relative to previous valuations.
The current trading price of $44.30 is significantly below the 200-day moving average of $72.44, indicating a prolonged downtrend or lack of recent momentum.
Boston Scientific (BSX) reported solid Q1 revenue growth of 11.6% year-over-year, but the company issued a softer full-year 2026 guidance update on April 22. This revision lowered expected net sales growth to between 7.0% and 8.5%, down from an earlier range of 10.5% to 11.5%. The primary driver for this reduction is identified as a slowdown in the electrophysiology (EP) segment, where competitor Medtronic appears to be gaining market share.
The article analyzes how this shift impacts Boston Scientific's investment narrative, which previously relied on the EP business as a key growth engine alongside its cardiovascular and MedSurg portfolios. Analysts had projected revenue of approximately $28.0 billion and earnings of $6.0 billion by 2029 under optimistic scenarios assuming sustained EP strength. The new guidance suggests these upbeat assumptions may need to be revisited, potentially challenging the company's previously bullish outlook.
Despite the headwinds in electrophysiology, the company maintains a diversified platform and continues to invest in high-potential areas such as its WATCHMAN device and pulsed field ablation technology. The core investment question now centers on whether Boston Scientific can stabilize EP growth while navigating increased competition from Medtronic. Consequently, EP execution has become the critical short-term catalyst and risk factor for investors evaluating the stock's near-term trajectory.
📉 2026 sales growth guidance lowered to 7.0%–8.5%.
⚡ EP segment slowdown due to Medtronic market share gain.
📊 Q1 revenue grew 11.6% despite EP concerns.
🛡️ Cardiovascular and MedSurg portfolios offset EP weakness.
🚀 Investing in WATCHMAN device and pulsed field ablation.
📉 Boston Scientific lowered its full-year 2026 net sales growth guidance to a range of 7.0% to 8.5%, down from an initial expectation of 10.5% to 11.5%.
⚡ The guidance reduction is directly attributed to a slowdown in the electrophysiology (EP) segment, where competitor Medtronic is gaining market share.
📊 Q1 2026 results showed strong overall revenue growth of 11.6%, but this momentum is now tempered by concerns over EP performance.
🔮 Previous optimistic analyst projections for 2029 included $28.0 billion in revenue and $6.0 billion in earnings, assumptions that may need revision.
🛡️ The company's diversified portfolio of cardiovascular and MedSurg products is expected to offset weakness in the electrophysiology segment.
🚀 Boston Scientific continues to invest in high-potential areas including its WATCHMAN device and pulsed field ablation technology.
⚖️ EP execution has become the key short-term catalyst and primary risk factor for the company's investment narrative.
Bullish Signals
Q1 revenue grew 11.6% year-over-year.
Diversified portfolio offsets EP segment weakness.
Risk Factors
Full-year 2026 sales guidance cut from 10.5%-11.5% to 7.0%-8.5%.
Electrophysiology segment slowdown as Medtronic gains market share.
2029 revenue projection of $28.0 billion may need revision.
Bullish Signals
Boston Scientific reported solid Q1 revenue growth of 11.6% year-over-year, demonstrating underlying business strength despite guidance cuts.
The company maintains a broad and diversified portfolio across cardiovascular and MedSurg segments that can offset specific weaknesses in electrophysiology.
Risk Factors
Full-year 2026 net sales growth guidance was cut significantly from an initial range of 10.5%-11.5% to a revised range of 7.0%-8.5%.
The electrophysiology segment is experiencing a slowdown with Medtronic gaining market share, challenging the company's primary growth engine assumptions.
Optimistic long-term revenue and earnings projections for 2029 (e.g., $28.0 billion revenue) may need to be revisited given current competitive pressures.
Banque Transatlantique SA increased its stake in Boston Scientific Corporation (NYSE:BSX) by 13.0% during the fourth quarter, purchasing an additional 139,431 shares to own a total of 1,211,331 shares valued at $115.46 million. This position represents 2.8% of the bank's portfolio and marks it as the institution's 10th largest holding. Other institutional investors also adjusted their positions, with Ieq Capital LLC increasing its stake by 97.0% to own 123,592 shares worth $13.28 million, while Main Street Financial Solutions LLC grew its holdings by 35.3%.
In insider trading activity, Director Edward J. Ludwig purchased 3,580 shares at an average price of $56.68 per share on May 20th, increasing his total ownership to 25,359 shares valued at approximately $1.44 million. Director Cheryl Pegus also acquired 1,770 shares at $56.49 per share. Over the last 90 days, insiders have collectively acquired 9,800 shares worth $554,012, though they still own only 0.34% of the company's total stock.
Financially, Boston Scientific reported Q1 earnings of $0.80 per share, beating the consensus estimate of $0.79, with revenue reaching $5.20 billion, an 11.6% year-over-year increase. The company provided guidance for Q2 2026 EPS between $0.82 and $0.84, and full-year FY 2026 EPS between $3.34 and $3.41. Additionally, the board initiated a new share buyback program authorizing the repurchase of up to $5.00 billion in shares, representing up to 6.4% of its outstanding stock.
Analyst sentiment remains mixed with recent price target adjustments. Leerink Partners lowered its target from $87.00 to $74.00 while maintaining an 'outperform' rating, and Barclays reduced its objective from $96.00 to $89.00 with an 'overweight' rating. Goldman Sachs set a $71.00 target, and Raymond James lowered its target to $88.00 but kept an 'outperform' rating. The consensus price target stands at $85.08 based on 29 analyst ratings, predominantly 'Buy' or 'Strong Buy', though Weiss Ratings downgraded the stock to a 'hold (c-)'.
🏦 Banque Transatlantique added 139,431 shares worth $115.46 million in Q4.
📈 Ieq Capital boosted stake by 97% to own 123,592 shares.
💼 Director Edward Ludwig bought 3,580 shares for $202,914 on May 20.
📊 Q1 earnings beat with $0.80 EPS and $5.20 billion revenue growth.
🔄 Company authorized new $5.00 billion share buyback program approved May 18.
🏦 Banque Transatlantique SA increased its BSX holdings by 13.0% in Q4, adding 139,431 shares for a total value of $115.46 million.
📈 Ieq Capital LLC significantly boosted its stake by 97.0%, now owning 123,592 shares valued at $13.28 million.
💼 Director Edward J. Ludwig purchased 3,580 shares on May 20th for a total of $202,914.40.
📊 Q1 earnings beat expectations with $0.80 EPS versus the $0.79 consensus estimate.
💰 Revenue reached $5.20 billion, marking an 11.6% increase compared to the previous year.
🔄 The company authorized a new $5.00 billion share buyback program approved on May 18th.
📉 Leerink Partners lowered its price target to $74.00 while maintaining an 'outperform' rating.
📉 Barclays reduced its price objective to $89.00 with an 'overweight' rating.
📈 Goldman Sachs set a price target of $71.00 in a research note released on May 28th.
🏥 Boston Scientific focuses on less-invasive procedures for cardiovascular, digestive, and urologic conditions.
📉 Weiss Ratings downgraded the stock from 'hold (c)' to 'hold (c-)' on May 13th.
🎯 The consensus analyst price target is currently set at $85.08.
Bullish Signals
EPS beat at $0.80 vs $0.79 estimate.
Revenue grew 11.6% YoY to $5.20 billion.
$5.00 billion share buyback program initiated.
Insiders bought 9,800 shares worth $554,012.
Strong ROE of 19.17% and 17.29% net margin.
Risk Factors
Barclays cut price objective to $89.00.
Weiss Ratings downgraded stock to hold (c-).
Goldman Sachs lowered target to $71.00.
Bullish Signals
The company reported a solid earnings beat with $0.80 EPS, exceeding the consensus estimate of $0.79 by $0.01.
Revenue grew to $5.20 billion, representing an 11.6% year-over-year increase driven by strong performance.
The board initiated a substantial $5.00 billion share buyback program, signaling management confidence in the stock's value.
Insiders have been net buyers over the last 90 days, acquiring 9,800 shares worth $554,012.
Major institutional investors like Banque Transatlantique SA and Ieq Capital LLC are significantly increasing their positions.
The company maintains a strong Return on Equity of 19.17% and a healthy net margin of 17.29%.
Risk Factors
Barcls reduced its price objective from $96.00 to $89.00, suggesting a more cautious outlook.
Weiss Ratings downgraded the stock from 'hold (c)' to 'hold (c-)', reflecting some analyst concern.
Goldman Sachs set a lower price target of $71.00 compared to previous higher valuations.
Boston Scientific (BSX) shares are drawing mixed attention as short interest rose sharply in May, signaling increased bearish positioning or hedging among traders. Despite this uptick in skepticism, Wall Street analysts maintain a broadly positive view, with the stock carrying an average rating of 'Moderate Buy' and a consensus price target of approximately $85.08 per share. The stock recently traded around $46.69 to $46.91, reflecting modest short-term consolidation and minor declines following a period of steady pullbacks in mid-June.
The divergence between rising short interest and supportive analyst ratings highlights differing perspectives on the company's valuation and near-term outlook. While some market participants appear cautious regarding potential downside or macroeconomic factors affecting the healthcare sector, institutional investors and analysts emphasize Boston Scientific's diversified portfolio across cardiovascular, electrophysiology, endoscopy, and neuromodulation markets. This breadth is seen as a stabilizing factor that supports long-term earnings growth and shareholder value creation.
Strategic developments further bolster the company's positive outlook, specifically a reported agreement to invest up to $1.5 billion in MiRus, a firm specializing in transcatheter aortic valve replacement (TAVR) technology. This investment includes an option for Boston Scientific to acquire the TAVR operation outright, positioning the company to expand its footprint in a high-growth structural heart therapy segment. Analysts view this move as a significant growth vector that could drive future revenue synergies and market share gains against competitors like Abbott and Edwards Lifesciences.
📉 Short interest in BSX rose significantly during May.
📈 Analysts rate stock 'Moderate Buy' with $85.08 target.
💰 Company invests up to $1.5B in MiRus TAVR.
🏥 Operates across cardiovascular, electrophysiology, and other markets.
📊 Shares consolidate after minor declines over three days.
📉 Short interest in Boston Scientific rose significantly during May, indicating heightened bearish positioning or hedging activity among traders.
📈 Analysts maintain a 'Moderate Buy' rating with a consensus price target of $85.08, implying substantial upside from the current trading level near $47.
💰 Boston Scientific agreed to invest up to $1.5 billion in MiRus's TAVR business, including an option to acquire the operation outright.
🏥 The company operates across diverse medical technology markets including cardiovascular, electrophysiology, endoscopy, urology, and neuromodulation.
📊 Recent trading activity shows BSX shares in a short-term consolidation phase with minor declines over three consecutive days in mid-June.
🔬 The strategic investment in MiRus targets the fast-growing structural heart therapy sector, specifically transcatheter aortic valve replacement procedures.
🏛️ Boston Scientific is a well-established component of major equity benchmarks, held by index funds and active managers focused on healthcare.
⚖️ Market sentiment reflects a coexistence of valuation concerns from short sellers and long-term growth optimism from institutional analysts.
Bullish Signals
Analysts rate Moderate Buy with $85.08 target vs $47 price.
Securing strategic stake in MiRus TAVR business for growth.
Diversified mix across cardiovascular, endoscopy, urology, and neuromodulation.
Robust institutional ownership ensures stability and liquidity.
$1.5 billion commitment to MiRus drives future revenue.
Risk Factors
Short interest surged in May.
Stock fell 0.55% to $46.91 on June 12.
Bullish Signals
Analysts maintain a 'Moderate Buy' rating with a consensus price target of $85.08, suggesting significant upside potential from the current price of approximately $47.
The company is securing a strategic stake in MiRus's TAVR business, positioning itself to capture growth in the rapidly expanding structural heart therapy market.
Boston Scientific possesses a diversified product mix across cardiovascular, endoscopy, urology, and neuromodulation, which helps smooth performance across economic cycles.
The company has a robust institutional ownership base and is included in major equity benchmarks, providing stability and liquidity for investors.
Strategic investments like the $1.5 billion commitment to MiRus demonstrate management's focus on expanding addressable markets and driving future revenue synergies.
Risk Factors
Short interest has increased sharply in May, indicating that a subset of market participants is positioning for potential downside or hedging existing exposure.
The stock has experienced a three-day losing streak in mid-June, with shares falling approximately 0.55% on Friday, June 12, to close at $46.91.
Boston Scientific (BSX) shares have declined over 50% from recent peaks, currently trading near $48 following a reduction in guidance. Investors are closely monitoring the impact of slower growth in key segments, specifically WATCHMAN and ablation technologies. Despite the short-term selloff, analysts maintain elevated price targets ranging between $84 and $135, suggesting the market may have overreacted to recent pressures.
The company reported Q1 2026 revenues of $5.2 billion, representing an 11.58% increase year-over-year. Insider trading activity shows a mixed but generally positive signal, with Chairman Michael F. Mahoney selling shares while other executives like David C. Habiger and Edward J. Ludwig made purchases. Congressional trading also reflects bullish sentiment, with Representative Gilbert Ray Cisneros Jr. making five purchases against one sale in the past six months.
Institutional investor positions are diverging significantly. While firms like FMR LLC and Capital World Investors reduced their holdings by over 20% and 43% respectively, others like Wellington Management Group and Franklin Resources increased their stakes substantially. Wall Street sentiment remains constructive, with four firms issuing buy ratings or outperform targets and a median price target of $84.5 set by 22 analysts.
📉 Shares tumbled over 50% from peaks, trading near $48.
💰 Q1 2026 revenues hit $5.2 billion, up 11.58%.
👔 CEO sold 160,901 shares for ~$15 million recently.
📈 Analyst median target is $84.5, ranging from $55 to $135.
🏛️ Rep Cisneros bought stock five times in six months.
📉 BSX shares have tumbled more than 50% from recent peaks, trading near $48 after a guidance reduction.
💰 Q1 2026 revenues reached $5.2 billion, marking an 11.58% increase compared to the prior year.
👔 CEO Michael F. Mahoney sold 160,901 shares for approximately $15 million over the last six months.
📈 Analysts maintain a median price target of $84.5, with targets ranging from $55 to $135.
🏛️ Representative Gilbert Ray Cisneros Jr. purchased BSX stock five times in the past six months.
📊 Institutional holdings are split, with FMR LLC reducing positions by 23.8% while Wellington Management added 94.0%.
🔬 Key growth segments WATCHMAN and ablation technologies are facing scrutiny due to slower growth.
💼 Four firms issued buy or outperform ratings on the stock in recent months.
Bullish Signals
Q1 2026 revenue grew 11.58% to $5.2 billion.
Median price target of $84.5 implies upside from $48.
Insiders David C. Habiger and Edward J. Ludwig bought shares.
Wellington Management Group increased position by 94.0%.
Four firms issue buy ratings with no recent sells.
Risk Factors
Stock declined >50% from recent peaks.
Guidance reduced causing sharp selloff.
Growth slowing in WATCHMAN and ablation segments.
Institutional selling: FMR -23.8%, Capital World -43.6%.
Bullish Signals
Q1 2026 revenue grew by 11.58% year-over-year to $5.2 billion, demonstrating underlying business strength despite the stock price decline.
Analysts maintain a median price target of $84.5, which is significantly higher than the current trading price near $48, implying substantial upside potential.
Insider buying activity includes purchases by David C. Habiger and Edward J. Ludwig, signaling confidence from senior management despite CEO sales.
Major institutional investors like Wellington Management Group (+94.0%) and Franklin Resources (+155.4%) have increased their positions in Q1 2026.
Wall Street consensus is bullish with four firms issuing buy or outperform ratings and no sell ratings issued recently.
Risk Factors
The stock has declined more than 50% from recent peaks, indicating significant short-term investor concern and volatility.
Guidance was reduced, which directly contributed to the sharp selloff in share price.
Growth is slowing in key segments including WATCHMAN and ablation technologies, raising questions about future revenue drivers.
Significant institutional selling occurred in Q1 2026, with FMR LLC reducing its portfolio by 23.8% and Capital World Investors by 43.6%.
The U.S. Food and Drug Administration issued a warning letter to Boston Scientific on Tuesday, August 23, 2005, citing "serious regulatory problems" at the company's medical device distribution plant in Massachusetts. The FDA specifically noted that heart stents were shipped to hospitals despite identified quality issues. This disclosure caused Boston Scientific shares to drop nearly five percent in morning trading, reaching a new 52-week low, while its Canadian partner, Angiotech Pharmaceuticals Inc., saw shares fall about two percent on the Toronto Stock Exchange.
The warning letter highlighted problems with shipments of Taxus drug-coated stents, which are Boston Scientific's top-selling product, as well as Vaxcel implantable infusion ports and Symmetry catheters used to insert medical devices. Stents are metal-mesh devices designed to prop open coronary arteries following surgeries that clear blockages. In response, Boston Scientific stated it is actively addressing every point raised in the letter, noting that corrective actions have been completed in many areas and that none of the cited shipment problems harmed patients.
The company noted a previous recall last summer involving nearly 100,000 units of the Taxus stent and another non-drug-coated model due to a manufacturing defect that has since been fixed. Angiotech Pharmaceuticals, which derives most of its revenue and profit from royalties on Boston Scientific Corp., was also affected by the news as its shares declined alongside Boston Scientific's stock price.
🏥 FDA warned Boston Scientific over quality issues at its Massachusetts plant.
📉 Shares dropped 5% as Taxus stents faced regulatory scrutiny.
✅ Company claims corrective actions are complete with no patient harm.
🔄 Previous recall of 100,000 units was due to a fixed defect.
💰 Partner Angiotech shares fell 2% on royalty-linked revenue concerns.
🏥 The U.S. FDA issued a warning letter to Boston Scientific regarding serious regulatory problems at its Massachusetts distribution plant.
💔 Heart stents were shipped to hospitals despite known quality issues, according to the FDA disclosure.
📉 Boston Scientific shares dropped nearly 5% in Tuesday morning trading, reaching a new 52-week low.
🇨🇦 Angiotech Pharmaceuticals Inc., Boston Scientific's Canadian partner, saw its shares fall about 2% on the Toronto Stock Exchange.
🔬 The FDA letter specifically cited quality problems with Taxus drug-coated stents, Vaxcel implantable infusion ports, and Symmetry catheters.
💊 Taxus drug-coated stents are Boston Scientific's top-selling product and were included in the regulatory warning.
🩺 Stents are metal-mesh devices used to prop open coronary arteries after surgeries to clear blockages.
✅ Boston Scientific stated it is actively working on every point raised in the FDA letter.
🛠️ The company reported completing corrective actions in many areas addressed by the FDA.
🚑 Boston Scientific confirmed that none of the shipment problems cited in the letter harmed patients.
🔄 Last summer, Boston Scientific recalled nearly 100,000 units of Taxus stents due to a manufacturing defect.
🔧 The company has since fixed the manufacturing defect that led to the previous recall.
💰 Angiotech Pharmaceuticals derives most of its revenue and profit from royalties on Boston Scientific Corp.
Bullish Signals
Company actively addressing all FDA letter points.
Corrective actions completed in many regulatory areas.
No shipment problems harmed patients per management.
Recalled 100,000 Taxus stents; defect now fixed.
Risk Factors
FDA warned Boston Scientific over serious regulatory problems at MA plant.
FDA cited Taxus stent shipment problems, top seller.
Previous recall hit 100k units due to defects.
Partner Angiotech shares fell 2% on royalty impact.
Bullish Signals
Boston Scientific stated it is actively working on every point raised in the FDA letter.
The company reported completing corrective action in many areas identified by regulators.
Management confirmed that none of the problems with shipments cited in the FDA letter harmed patients.
The company previously recalled nearly 100,000 units of Taxus stents due to a manufacturing defect that has since been fixed.
Risk Factors
The U.S. FDA issued a warning letter citing 'serious regulatory problems' at Boston Scientific's medical device distribution plant in Massachusetts.
Heart stents were shipped to hospitals despite identified quality issues, raising concerns about product safety and compliance.
Boston Scientific shares dropped nearly five percent in morning trading to reach a new 52-week low following the disclosure.
The FDA specifically cited problems with shipments of Taxus drug-coated stents, which is Boston Scientific's top-selling product.
A previous recall last summer involved nearly 100,000 units of the Taxus stent and another non-drug-coated model due to a manufacturing defect.
Angiotech Pharmaceuticals Inc., a Canadian partner that derives most of its revenue and profit from royalties on Boston Scientific Corp., saw shares fall about two percent.
Boston Scientific Corporation (NYSE: BSX) has initiated a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank. The company immediately received approximately 30.4 million shares, representing 80% of the total repurchase value based on the May 15 closing price. This transaction is part of a previously authorized $5 billion share buyback program.
The accelerated share repurchase is expected to be accretive to Boston Scientific's 2026 adjusted earnings per share by approximately $0.02, effectively improving its financial guidance issued in April. Upon completion of the agreement by June 30, this transaction will leave $3 billion remaining under the company's total share repurchase authorization.
The move is a key component of Boston Scientific's capital allocation strategy, aiming to reduce share count and deliver increased value to shareholders while maintaining resources for operational and strategic goals. The company operates in medical devices for interventional specialties with segments including MedSurg and Cardiovascular.
📈 Boston Scientific initiates $2B accelerated share repurchase agreement.
💰 Immediately received 30.4 million shares representing 80% value.
📅 Final share count determined by June 30 completion.
📊 Leaves $3B remaining under total share repurchase authorization.
💹 Expected to be accretive to 2026 EPS by $0.02.
📈 Boston Scientific initiates a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank.
💰 The company immediately received approximately 30.4 million shares representing 80% of the repurchase value.
📅 The final number of shares will be determined upon completion of the agreement by June 30.
📊 This transaction leaves $3 billion remaining under the company's total share repurchase authorization.
💹 The ASR is expected to be accretive to 2026 adjusted earnings per share by $0.02.
🚀 This effectively improves the financial guidance previously issued in April.
🏥 Boston Scientific specializes in medical devices for interventional medical specialties with MedSurg and Cardiovascular segments.
Bullish Signals
$2B share buyback signals confidence and returns capital.
Expected to accrete $0.02 to 2026 EPS.
Improves previously issued financial guidance for the year.
$3B buyback authorization remains available for flexibility.
Bullish Signals
The company is executing a significant $2 billion share buyback, signaling confidence in its stock and commitment to returning capital to shareholders.
The accelerated share repurchase is explicitly expected to be accretive to 2026 adjusted earnings per share by $0.02.
This transaction improves the company's previously issued financial guidance for the year.
A substantial portion of the buyback authorization ($3 billion) remains available for future use, providing flexibility in capital allocation.
Boston Scientific Corporation (NYSE: BSX) is identified as one of the five most oversold S&P 500 stocks in 2026, having experienced a share price decline of 55.15% from its 52-week high. The stock's recent performance was influenced by a downgrade from Wolfe Research on May 29, which shifted its rating from Outperform to Peer Perform after the company reported slowing sales growth for its Watchman implant, a device used to reduce stroke risk. This marks the end of a four-year bullish outlook from the firm.
Following the Watchman update, TD Cowen also lowered its price target on BSX to $61 from $80, though it maintained a Buy rating. Despite these analyst revisions, the stock remains rated as a Strong Buy by 27 analysts with an average share price upside of 70% as of May 29. Boston Scientific is described as a global medical technology company that manufactures and markets devices for various interventional medical specialties.
📉 BSX shares dropped 55% from highs, ranking among S&P 500's most oversold in 2026.
⚠️ Wolfe Research downgraded the stock to Peer Perform after four years of bullishness.
💰 TD Cowen cut price target to $61 but kept a Buy rating despite revisions.
📉 Boston Scientific (BSX) shares have declined 55.15% from their 52-week high, marking it as one of the most oversold S&P 500 stocks in 2026.
⚠️ Wolfe Research downgraded BSX from Outperform to Peer Perform on May 29, ending a four-year bullish outlook for the firm.
🩺 The downgrade follows Boston Scientific's announcement that sales growth for its Watchman implant is slowing due to reduced stroke risk.
📊 Analysts now anticipate 7% organic growth for BSX in 2027, which would value the stock at roughly $50 per share.
💰 TD Cowen lowered its price target on BSX from $80 to $61 but maintained its Buy rating despite the recent revisions.
📈 Despite negative analyst actions, BSX remains a Strong Buy based on 27 analysts with an average upside of 70% as of May 29.
🏥 Boston Scientific is a global medical technology company that manufactures and markets devices for various interventional medical specialties.
TD Cowen maintains Buy rating with $61 price target.
Risk Factors
Wolfe downgraded stock to Peer Perform citing slowing sales.
TD Cowen cut price target to $61 from $80.
Wolfe expects only 7% organic growth for Boston Scientific.
Bullish Signals
Despite recent analyst downgrades, BSX remains a Strong Buy based on recommendations from 27 analysts.
The stock has an average share price upside of 70% as of the close on May 29, indicating significant potential for growth.
TD Cowen maintained a Buy rating on the stock even after lowering its price target to $61 from $80.
Risk Factors
Wolfe Research downgraded the stock from Outperform to Peer Perform on May 29, ending a four-year bullish outlook due to slowing sales growth for the Watchman implant.
TD Cowen lowered its price target on BSX to $61 from $80 following the Watchman update, reflecting reduced analyst valuation expectations.
Wolfe Research now anticipates only 7% organic growth for Boston Scientific in 2027, suggesting a slowdown in future revenue expansion.
Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific (BSX) with a price target of $89.00, citing strong fundamentals despite recent market volatility. The recommendation follows a similar stance from TD Cowen, which reiterated a Buy rating with an $80.00 price target based on the company's latest earnings for the quarter ending March 31. Boston Scientific reported quarterly revenue of $5.2 billion and net profit of $1.34 billion, representing significant growth compared to last year's figures of $4.66 billion in revenue and $674 million in net profit.
Corporate insider sentiment remains positive, with data from TipRanks indicating increased buying activity among 61 insiders over the past quarter. Notably, Edward Ludwig, a Director at BSX, purchased 3,580 shares for approximately $202,914 earlier this month. While Miksic covers the broader Healthcare sector including peers like Johnson & Johnson and Becton Dickinson, his specific focus on Boston Scientific highlights its long-term growth potential even as it navigates near-term headwinds related to the WATCHMAN product line.
📈 Analysts maintain Buy ratings with price targets ranging from $75 to $89.
💰 Q1 revenue hit $5.2B while net profit surged to $1.34 billion.
👥 Insider buying is strong, highlighted by a director's $203k share purchase.
📈 Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific (BSX) with a price target of $89.00.
💰 The company reported quarterly revenue of $5.2 billion and net profit of $1.34 billion for the quarter ending March 31.
📊 Revenue grew from $4.66 billion last year, while net profit increased significantly from $674 million to $1.34 billion.
👥 Corporate insider sentiment is positive with 61 insiders showing increased buying activity over the past quarter.
🏦 Director Edward Ludwig recently purchased 3,580 shares for a total value of $202,914.40 earlier this month.
📉 TD Cowen reiterated a Buy rating on the stock but set a lower price target of $80.00 compared to Barclays.
🩺 Analyst Robbie Marcus cited intact long-term growth outlook despite near-term headwinds related to WATCHMAN products.
🏥 Miksic covers the Healthcare sector including peers like Johnson & Johnson and Becton Dickinson.
📊 TipRanks data indicates Miksic has a 49.48% success rate on recommended stocks with an average return of 1.5%.
⚠️ The article notes various other analyst actions including Stifel lowering the price target to $75 from $85.
Bullish Signals
Barclays maintains Buy on BSX with $89 target.
TD Cowen reiterates Buy with $80 target.
Revenue grew to $5.2B and profit to $1.34B.
Insider buying rose, led by Director Ludwig's $202k purchase.
Stock crashing today signals significant volatility and negative sentiment.
Bullish Signals
Barclays analyst Matt Miksic maintained a Buy rating on Boston Scientific (BSX) with a price target of $89.00.
TD Cowen also reiterated a Buy rating on the stock with a $80.00 price target.
The company reported quarterly revenue of $5.2 billion and net profit of $1.34 billion, representing significant growth from last year's $4.66 billion revenue and $674 million net profit.
Corporate insider sentiment is positive with an increase in insider buying over the past quarter, highlighted by Director Edward Ludwig purchasing 3,580 shares for $202,914.40.
Analysts cite an intact long-term growth outlook and TAVR expansion as key drivers supporting the stock despite near-term headwinds.
Risk Factors
Boston Scientific's WatchMAN device faces near-term headwinds that could impact short-term revenue growth despite long-term optimism.
Analyst Stifel lowered Boston Scientific's price target from $85 to $75, indicating a reduction in valuation expectations.
The article mentions the stock is 'crashing today', suggesting significant recent volatility or negative market sentiment.
Boston Scientific Corp (BSX) shares fell to a 52-week low near $56 as of May 8, 2026, reflecting a roughly 46% decline from the prior year's high of $109.50. The stock dropped 4.7% following its latest earnings report, which saw EPS of $0.80 beating the consensus estimate of $0.79 and revenue reaching $5.20 billion, an 11.6% increase over the previous year. Despite this top-line success and the earnings beat, the market reaction was negative due to lower near-term guidance for the second quarter of 2026 (EPS of $0.82–$0.84) and a full-year 2026 EPS outlook of $3.34–$3.41, which analysts interpreted as a cautious stance. The company's price action under these conditions also saw lowered analyst targets contributing to the downward pressure.
Boston Scientific operates in the global medical device sector, focusing on minimally invasive technologies across specialties such as interventional cardiology and endoscopy, which are its primary revenue drivers. Core products include coronary stents, structural heart devices, and gastrointestinal diagnostic tools, serving an aging population and benefiting from shifts toward ambulatory care. While the company maintains a strong global footprint and diversified portfolio in areas like urology and neuromodulation, recent performance highlights the tension between solid top-line growth and investor concerns regarding near-term margin expansion and the pace of revenue realization against a backdrop of regulatory and reimbursement risks.
📉 Shares plummeted 46% from highs despite beating EPS expectations with record revenue growth.
Revenue grew approximately 11.6% year over-year to $5.20 billion for the latest reported quarter, exceeding the consensus estimate of $5.19 billion.
The company beat earnings per share estimates with actual results of $0.80 versus a consensus of $0.79.
Boston Scientific maintains a diversified product portfolio across key growth segments including interventional cardiology and endoscopy, which represent the largest portions of revenue.
Recent product launches and technology upgrades in the endoscopy segment have supported double-digit revenue growth in certain quarters.
The company benefits from favorable demographic trends such as aging populations and rising chronic disease prevalence, which drive long-term demand for its devices.
Boston Scientific has a strong global footprint with significant expansion potential in emerging markets where demand for advanced medical devices is growing.
Its focus on technologies enabling less invasive procedures aligns with broader healthcare trends toward outpatient care and shorter hospital stays, supporting sustained growth.
The company operates through multiple segments including urology, neuromodulation, and peripheral interventions, which help diversify its revenue base and reduce dependence on any single therapy area.
Risk Factors
Shares fell 4.7% on May 8, 2026, reaching a 52-week low near $56 despite reporting a modest earnings beat of $0.80 versus the consensus of $0.79.
The stock has declined roughly 46% from its 52-week high of about $109.50 over the past year, indicating significant investor skepticism or bearish sentiment.
Although revenue grew 11.6% year over year to $5.20 billion, the company issued reduced near-term guidance for the second quarter ($0.820–$0.840 EPS) and full-year 2026 ($3.340–$3.410 EPS), signaling a cautious or slowing outlook.
Analysts have lowered their price targets, contributing to downward pressure on the stock price even after positive operational results.
Boston Scientific (NYSE:BSX) is highlighted as a profitable alternative to high-risk "story stocks," characterized by consistent revenue and profit generation. The company has demonstrated significant earnings per share (EPS) growth, increasing by 60% annually over the last three years, a trend that often attracts long-term investors despite historical sustainability concerns. Revenue for the period reported grew by 17% to reach US$21 billion, while EBIT margins remained stable, indicating strong operational efficiency alongside top-line expansion.
Insider ownership serves as another validation of the company's fundamentals, with management holding a stake worth approximately US$158 million. Although this represents only 0.2% of the total US$84 billion market capitalization due to the company's large size, it signals alignment between management actions and shareholder interests. The article suggests that while the stock possesses strong growth metrics and insider confidence, its valuation via P/E ratios remains an area for further investigation by retail investors looking to buy cheap.
The analysis concludes that Boston Scientific represents a potential inflection point where fast EPS growth meets robust revenue expansion, making it a candidate for a watchlist. The content explicitly states that this fundamental analysis does not include the latest price-sensitive announcements or qualitative material, and serves as an unbiased commentary rather than specific financial advice to buy or sell.
📈 Boston Scientific achieved 60% annual EPS growth and $21 billion in revenue.
💰 The company holds a $84 billion market cap with significant insider alignment.
⚠️ Investors should verify P/E ratios and remember that rapid high growth is often unsustainable.
📈 Boston Scientific (NYSE:BSX) has grown its earnings per share (EPS) by 60% annually over the last three years.
💰 The company reported a 17% revenue increase for the period, reaching a total of US$21 billion.
📊 While EBIT margins remained stable, the combination of EPS growth and revenue expansion is considered positive by investors.
👔 Insider ownership is notable, with management holding a stake worth approximately US$158 million.
📉 This insider stake represents about 0.2% of the total company value but demonstrates alignment between executives and shareholders.
⚠️ The article notes that while recent high EPS growth is encouraging, such rapid growth levels rarely last indefinitely.
💸 Boston Scientific has a market capitalization of around US$84 billion, distinguishing it from smaller "story stocks" without profits.
📈 The company operates in the healthcare sector and could benefit from AI advancements in diagnostics and drug discovery.
🔍 Analysts suggest checking if the stock is trading at a high or low P/E relative to its industry before investing.
⚖️ The analysis relies on historical data and analyst forecasts rather than latest price-sensitive announcements.
🏛️ Boston Scientific is one of 20 US companies under US$10bn market cap highlighted for potential growth in healthcare AI.
📝 Readers are advised that the content is general information and not specific financial advice to buy or sell the stock.
📉 The text cautions investors against putting money into loss-making companies driven solely by emotional "story" investing.
🌱 A business reaching an inflection point, indicated by fast EPS growth, may offer investment opportunities for long-term holders.
Bullish Signals
EPS grew 60% annually over the last three years.
Revenue rose 17% to reach US$21 billion.
Executives hold a US$158 million insider stake.
Consistent EPS growth suggests further upside potential.
Boston Scientific has grown its earnings per share (EPS) by 60% per year over the last three years, which is considered a significant positive by successful long-term investors.
The company reported impressive revenue growth of 17%, reaching US$21 billion for the period, indicating strong business fundamentals and top-line expansion.
Management holds an enviable insider stake worth US$158 million, signaling alignment between executives and shareholders despite the holding representing only 0.2% of the large US$84 billion company.
Consistent EPS growth can serve as a sign that the business has reached an inflection point, suggesting there may be further upside potential for investors.
Risk Factors
While Boston Scientific has grown EPS by 60% over the last three years, such high rates of growth rarely last long, suggesting potential future deceleration.
EBIT margins remained unchanged over the last year despite revenue growth, indicating a lack of operational efficiency improvement or margin expansion in recent periods.
Insider ownership is only 0.2% of the business, which, while showing alignment, is relatively low for a company of this size compared to typical insider stakes that might signal stronger confidence.
The analysis explicitly states it does not factor in latest price-sensitive company announcements or qualitative material, creating information risk for investors relying solely on this data.
The article notes that valuation work has not yet been done regarding whether the stock is trading on a high P/E relative to its industry, introducing downside risk if valuations are already elevated.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)